Department of Interventional Radiology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Front Immunol. 2023 Apr 25;14:1163656. doi: 10.3389/fimmu.2023.1163656. eCollection 2023.
Abdominal lymph node (ALN) metastasis is associated with a poor prognosis in patients with hepatocellular carcinoma (HCC) because of the limited number of effective therapeutic options available. Immunotherapy with immune checkpoint inhibitors, such as those targeting programmed death receptor-1 (PD-1), have produced encouraging results in patients with advanced HCC. Here, we report a complete response (CR) in a patient with advanced HCC and ALN metastasis after combination treatment with tislelizumab (a PD-1 inhibitor) and locoregional therapy.
A 58-year-old man with HCC experienced progressive disease with multiple ALN metastases after undergoing transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), and laparoscopic resection. Because the patient did not wish to receive systemic therapy, including chemotherapy and targeting therapy, we prescribed tislelizumab (as a single immunotherapeutic agent) together with RFA. After four tislelizumab treatment cycles, the patient achieved a CR without tumor recurrence for up to 15 months.
Tislelizumab monotherapy can be effectively used to treat advanced HCC with ALN metastasis. Moreover, the combination of locoregional therapy and tislelizumab is likely to further increase therapeutic efficacy.
肝癌（HCC）患者的腹部淋巴结（ALN）转移与预后不良相关，因为目前有效的治疗选择有限。免疫检查点抑制剂（如针对程序性死亡受体-1（PD-1）的抑制剂）的免疫治疗在晚期 HCC 患者中取得了令人鼓舞的结果。在这里，我们报告了一例晚期 HCC 合并 ALN 转移患者在接受替雷利珠单抗（一种 PD-1 抑制剂）联合局部治疗后的完全缓解（CR）。
一名 58 岁男性，因 HCC 接受经导管动脉化疗栓塞术（TACE）、射频消融术（RFA）和腹腔镜切除术治疗后出现疾病进展，且伴有多个 ALN 转移。由于患者不愿意接受包括化疗和靶向治疗在内的全身治疗，我们开了替雷利珠单抗（作为单一免疫治疗药物）联合 RFA。在接受了四个替雷利珠单抗治疗周期后，患者达到了 CR，并且在长达 15 个月的时间内没有肿瘤复发。
替雷利珠单抗单药治疗晚期 HCC 合并 ALN 转移是有效的。此外，局部治疗联合替雷利珠单抗可能会进一步提高治疗效果。
